Warren Huff, CEO of Reata Pharmaceuticals, and CNBC's Meg Tirrell join 'Power Lunch' to discuss Reata's new drug for treating a rare neurological disorder receiving FDA approval.
A major regulatory approval lit a fire underneath Reata's shares this week.
Skyclarys is the first drug to be approved specifically for the treatment of Friedreich's ataxia and is also Reata Pharmaceuticals' (RETA) first commercial product
Cytokinetics President and CEO Robert Blum joins 'Power Lunch' to discuss the FDA's rejection of the company's heart failure drug, how FDA approval increases shareholder value and future treatment pla

Pharma Stock Surges After FDA Approves Treatment

02:30pm, Wednesday, 01'st Mar 2023
The shares of Reata Pharmaceuticals Inc  (NASDAQ:RETA) are up 178.5% at $86.81 this afternoon, after U.S. Food and Drug Administration (FDA) approved the drugmaker's Skyclarys treatment for Friedre
Biopharma company Reata Pharmaceuticals Inc (NASDAQ:RETA) was in the spotlight on Wednesday after a key approval from the US Food and Drug Administration (FDA) sent its stock soaring. The company ann
Markets are trying to rise, and these companies are helping out.
Shares of Reata Pharmaceuticals Inc. RETA soared about 175% in premarket trading on Wednesday, the day after the Food and Drug Administration approved Skyclarys, a treatment for Friedreich's ataxia, a
The FDA approves the pharmaceutical company's treatment for Friedreich's ataxia, which Citi analysts expect to generate peak U.S. revenue of around $1.2 billion.
Reata Pharmaceuticals won FDA approval for its neurological disease treatment late Tuesday, shortly after RETA stock was halted. The post Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approv
The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.'s treatment for Friedreich's ataxia, a rare inherited disease that causes damage to the nervous system.
The FDA will decide whether to approve a neurological disease drug from Reata Pharmaceuticals this week, but RETA stock plummeted Monday. The post Reata Stock Plummets As Official's Exit Shakes Up FDA
There are no sure things in the stock market. But here's an almost sure thing: Investing in stocks that sell for 100 times revenue will lead you to grief.
Reata Pharmaceuticals, Inc. (RETA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furthe
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE